Loading...
12 budesonide COVID-19 controlled studies, 5 RCTs
https://c19early.org/umeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+ STOIC Ramakrish.. (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control STOIC Ramakrish.. (RCT) 90% 0.10 [0.01-0.75] hosp./ER 1/70 10/69 STOIC Ramakrish.. (RCT) 67% 0.33 [0.15-0.72] no recov. 7/70 21/69 TOGETHER Reis (DB RCT) -200% 3.00 [0.12-73.5] death 1/738 0/738 CT1 TOGETHER Reis (DB RCT) 12% 0.88 [0.32-2.40] hosp. 7/738 8/738 CT1 TOGETHER Reis (DB RCT) 50% 0.50 [0.25-0.92] progression 13/738 27/738 CT1 Ramlall (ICU) 71% 0.29 [0.11-0.78] death 33 (n) 915 (n) Intubated patients PRINCIPLE Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 PRINCIPLE Yu (RCT) 6% 0.94 [0.44-1.98] ventilation 13/776 14/784 PRINCIPLE Yu (RCT) 52% 0.48 [0.23-1.01] ICU 10/771 21/779 PRINCIPLE Yu (RCT) 25% 0.75 [0.55-1.03] death/hosp. 72/787 116/1,069 PRINCIPLE Yu (RCT) 17% 0.83 [0.74-0.93] recov. time 787 (n) 1,069 (n) Al Sulaiman (ICU) 32% 0.68 [0.41-1.13] death 30/64 31/64 ICU patients MP 80%2 Al Sulaiman (ICU) 47% 0.53 [0.31-0.93] death 25/65 29/65 ICU patients MP 80%2 Alsultan (RCT) -7% 1.07 [0.42-2.71] death 5/14 7/21 TACTIC Agustí (RCT) -23% 1.23 [0.08-19.0] death 1/40 1/49 TACTIC Agustí (RCT) 39% 0.61 [0.12-3.17] progression 2/40 4/49 Yang -11% 1.11 [0.62-1.97] death 30/125 13/60 Samajdar 58% 0.42 [0.08-2.05] death 2/50 5/52 CT1 Samajdar 65% 0.35 [0.04-3.22] ventilation 1/50 3/52 CT1 Samajdar 69% 0.31 [0.09-1.07] hosp. 3/50 10/52 CT1 Samajdar 29% 0.71 [0.55-0.91] no recov. 50 (n) 52 (n) CT1 Samajdar 10% 0.90 [0.80-1.02] no recov. 50 (n) 52 (n) CT1 Lee 33% 0.67 [0.42-1.08] cases 19/1,674 95/5,345 Monserrat .. (PSM) 49% 0.51 [0.28-0.90] death n/a n/a Loucera 22% 0.78 [0.65-0.92] death 1,047 (n) 14,921 (n) Budesonide COVID-19 outcomes c19 early1 CT: study uses combined treatment 2 MP: multiple medications, percentage budesonide shown Favors budesonide Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit
